Anaptysbio, Inc (ANAB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Anaptysbio reported revenue of $234.6M, up 157.0% from $91.3M the year before. Net income was -$13.2M (a -5.6% net margin), or -$0.31 per diluted share. Operating margin was 20.4%. Operating activities generated $19.7M of cash, leaving $19.6M of free cash flow. At fiscal year end, Anaptysbio held $364.4M in total assets against $327.2M in total liabilities, including $238.2M of cash and equivalents.
Open the full interactive Anaptysbio financials → Quarterly statements, key ratios, valuation history and price charts.
Anaptysbio Key Stats
| Share Price | $45.59 |
|---|---|
| Market Cap | $1.31B |
| Revenue YoY Growth | +157.0% |
| 52-Week Range | $21.23 – $69.81 |
| Shares Outstanding | 28.7 million (basic, 2026 Q1) |
Anaptysbio Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $75.0M | $63.2M | $10.3M | $17.2M | $91.3M | $234.6M |
| Operating Income | -$23.9M | -$56.8M | -$115.2M | -$164.4M | -$114.9M | $47.9M |
| Pre-Tax Income | -$19.9M | -$57.8M | -$128.7M | -$163.6M | -$145.2M | -$13.1M |
| Income Tax | $0 | $0 | $24,000 | -$4,000 | $3,000 | $164,000 |
| Net Income | -$19.9M | -$57.8M | -$128.7M | -$163.6M | -$145.2M | -$13.2M |
| Diluted EPS | -$0.49 | -$1.41 | -$3.05 | -$4.05 | -$3.41 | -$0.31 |
Anaptysbio Quarterly Results
| 2025 Q2 | 2025 Q3 | 2025 Q4 | 2026 Q1 | |
|---|---|---|---|---|
| Revenue | $22.3M | $76.3M | $108.2M | $25.6M |
| Net Income | -$38.6M | $15.1M | $49.6M | -$52.9M |
| Diluted EPS | -$0.89 | $0.35 | $1.73 | -$1.84 |
Anaptysbio Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $250.5M | $495.7M | $71.3M | $36.0M | $123.1M | $238.2M |
| Current Assets | $396.6M | $553.9M | $447.2M | $406.8M | $431.9M | $350.2M |
| Total Assets | $416.6M | $643.1M | $610.4M | $452.4M | $483.8M | $364.4M |
| Current Liabilities | $19.8M | $16.1M | $26.1M | $37.4M | $45.4M | $38.6M |
| Total Liabilities | $19.8M | $286.6M | $348.3M | $364.3M | $413.0M | $327.2M |
| Shareholders' Equity | $396.7M | $356.4M | $262.1M | $88.1M | $70.9M | $37.2M |
Anaptysbio Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$14.2M | -$45.9M | -$73.6M | -$120.8M | -$135.3M | $19.7M |
| Cash From Investing | $94.5M | $38.8M | -$394.8M | $144.8M | $95.4M | $228.0M |
| Cash From Financing | -$879,000 | $252.3M | $44.0M | -$59.3M | $127.1M | -$132.6M |
| Free Cash Flow | -$14.7M | -$47.3M | -$74.0M | -$121.6M | -$135.7M | $19.6M |
Figures from Anaptysbio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Anaptysbio financials page for every line item.
Anaptysbio Company Profile
| Ticker | ANAB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | June 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001370053 |
Frequently Asked Questions
What was Anaptysbio's revenue in fiscal 2025?
Anaptysbio (ANAB) reported revenue of $234.6M for fiscal 2025.
What is Anaptysbio's annual revenue history?
Anaptysbio's annual revenue by fiscal year: 2020: $75.0M; 2021: $63.2M; 2022: $10.3M; 2023: $17.2M; 2024: $91.3M; 2025: $234.6M.
What was Anaptysbio's net income in fiscal 2025?
Anaptysbio reported net income of -$13.2M for fiscal 2025.
What was Anaptysbio's earnings per share (EPS) in fiscal 2025?
Anaptysbio's diluted EPS was -$0.31 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Anaptysbio generate in fiscal 2025?
Anaptysbio generated $19.6M of free cash flow in fiscal 2025.
What was Anaptysbio's revenue last quarter?
In its most recent reported quarter (2026 Q1), Anaptysbio reported revenue of $25.6M.
How many shares of Anaptysbio are outstanding?
Anaptysbio reported a weighted average of 28.7 million basic shares outstanding in 2026 Q1.
What is Anaptysbio's market cap?
Based on its latest closing price, Anaptysbio (ANAB) has a market capitalization of about $1.31B.
When does Anaptysbio's fiscal year end?
Anaptysbio's fiscal year end, as registered with the SEC, is June 30.
Where is Anaptysbio headquartered?
Anaptysbio lists its business address in San Diego, California in its SEC filings.